The burgeoning landscape of treatment for weight management and type 2 glucose intolerance is currently witnessing considerable interest surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 target agonists, significant differences in their pharmacological profiles and clinical investigation results are emergin… Read More

Showing promise in the landscape of excess body fat management, retatrutide is a unique approach. Unlike many existing medications, retatrutide works as a dual agonist, concurrently targeting both GLP peptide-1 (GLP-1) and glucose-responsive insulinotropic polypeptide (GIP) receptors. This simultaneous activation promotes various advantageous effec… Read More